These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 11432619)
1. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Di Raimondo F; Giustolisi R; Lerner S; Cacciola E; O'Brien S; Kantarjian H; Keating MJ Ann Oncol; 2001 May; 12(5):621-5. PubMed ID: 11432619 [TBL] [Abstract][Full Text] [Related]
2. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Hallek M; Langenmayer I; Nerl C; Knauf W; Dietzfelbinger H; Adorf D; Ostwald M; Busch R; Kuhn-Hallek I; Thiel E; Emmerich B Blood; 1999 Mar; 93(5):1732-7. PubMed ID: 10029603 [TBL] [Abstract][Full Text] [Related]
3. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Hallek M; Wanders L; Ostwald M; Busch R; Senekowitsch R; Stern S; Schick HD; Kuhn-Hallek I; Emmerich B Leuk Lymphoma; 1996 Aug; 22(5-6):439-47. PubMed ID: 8882957 [TBL] [Abstract][Full Text] [Related]
4. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Anaissie EJ; Kontoyiannis DP; O'Brien S; Kantarjian H; Robertson L; Lerner S; Keating MJ Ann Intern Med; 1998 Oct; 129(7):559-66. PubMed ID: 9758577 [TBL] [Abstract][Full Text] [Related]
5. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625 [TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Keating MJ; O'Brien S; Lerner S; Koller C; Beran M; Robertson LE; Freireich EJ; Estey E; Kantarjian H Blood; 1998 Aug; 92(4):1165-71. PubMed ID: 9694704 [TBL] [Abstract][Full Text] [Related]
7. Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors. Hallek M; Emmerich B; Strohmeyer S; Busch R; Reichle A; Senekowitsch R Klin Wochenschr; 1988 Aug; 66(16):718-23. PubMed ID: 3172680 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia. Stelmach P; Błoński JZ; Wawrzyniak E; Schweiger PE; Wilandt A; Majak PE; Robak T Postepy Hig Med Dosw (Online); 2016 Dec; 70(0):1321-1330. PubMed ID: 28100842 [TBL] [Abstract][Full Text] [Related]
9. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H; J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025 [TBL] [Abstract][Full Text] [Related]
10. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression. Matthews C; Catherwood MA; Morris TC; Kettle PJ; Drake MB; Gilmore WS; Alexander HD Eur J Haematol; 2006 Oct; 77(4):309-17. PubMed ID: 16856923 [TBL] [Abstract][Full Text] [Related]
11. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases]. Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412 [TBL] [Abstract][Full Text] [Related]
12. Prognostic features and therapeutical approaches in B-cell chronic lymphocytic leukemia: an update. Molica S; De Rossi G; Luciani M; Levato D Haematologica; 1995; 80(2):176-93. PubMed ID: 7628755 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone. Mauro FR; Gentile M; Mancini F; Giannarelli D; Guarini A; De Propriis MS; Cerretti R; Foa R Haematologica; 2002 Jun; 87(6):602-8. PubMed ID: 12031916 [TBL] [Abstract][Full Text] [Related]
14. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. O'Brien S; Kantarjian H; Beran M; Smith T; Koller C; Estey E; Robertson LE; Lerner S; Keating M Blood; 1993 Sep; 82(6):1695-700. PubMed ID: 8400226 [TBL] [Abstract][Full Text] [Related]
15. [Lipoprotein lipase and serum thymidine kinase level in chronic lymphocytic leukemia and their correlations with other prognostic factors]. Xu W; Shen QD; Yu H; Qiao C; Wu YJ; Liu Q; Zhu DX; Miao KR; Li JY Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):8-12. PubMed ID: 19563027 [TBL] [Abstract][Full Text] [Related]
16. Variant Richter's syndrome: a rare case of classical Hodgkin's lymphoma developing in a patient with chronic lymphocytic leukemia treated with fludarabine. Nemets A; Ben Dor D; Barry T; Ducach A; Blumental R; Ben Alon D; Lugassy G Leuk Lymphoma; 2003 Dec; 44(12):2151-4. PubMed ID: 14959863 [TBL] [Abstract][Full Text] [Related]
17. Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. Bosanquet AG; Johnson SA; Richards SM Br J Haematol; 1999 Jul; 106(1):71-7. PubMed ID: 10444165 [TBL] [Abstract][Full Text] [Related]